Document Detail

Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease.
MedLine Citation:
PMID:  10327154     Owner:  NLM     Status:  MEDLINE    
Recent evidence suggest the implication of transition metals leading to overproduction of free radicals as a possible causal factor in the death of nigral cells associated to Parkinson's disease (PD). Iron depots in the basal ganglia of PD patients have been described; in addition, contents of nigral copper have been found decreased, while its concentration in cerebrospinal fluid (CSF) is raised, particularly the free form of the metal. To search for a possible link between altered copper concentrations and PD, we advanced the hypothesis that ferroxidase activity of ceruloplasmin is decreased in the CSF of PD patients. We studied 35 untreated PD patients, 14 L-3,4-dihydroxyphenylalanine (L-DOPA)-treated PD patients and 26 controls. Both CSF ferroxidase activity and CSF copper content were measured and correlated with the clinical stage of the disease. We found that untreated PD patients had a significant reduction of 40% in CSF ferroxidase while CSF copper was slightly increased as compared with both the values in L-DOPA-treated PD patients and controls. We also found that the fraction of copper linked to ferroxidase in untreated PD is inversely related to the clinical stage of the disease.
M C Boll; J Sotelo; E Otero; M Alcaraz-Zubeldia; C Rios
Related Documents :
9562324 - Differentiation of idiopathic parkinson's disease from striatonigral degeneration and p...
9448574 - Complementary pet studies of striatal neuronal function in the differential diagnosis b...
3813934 - Learning deficit in parkinson's disease. comparison with alzheimer's disease and normal...
20096894 - Periodontal and coronary heart disease in patients undergoing coronary angiography.
6612754 - Influence of long-term administration of serum albumin on the prognosis of liver cirrho...
6237134 - Immune complexes and antinuclear, antinucleolar, and anticentromere antibodies in scler...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neuroscience letters     Volume:  265     ISSN:  0304-3940     ISO Abbreviation:  Neurosci. Lett.     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-07-01     Completed Date:  1999-07-01     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7600130     Medline TA:  Neurosci Lett     Country:  IRELAND    
Other Details:
Languages:  eng     Pagination:  155-8     Citation Subset:  IM    
Department of Neurology, National Institute of Neurology and Neurosurgery Manuel Velsasco Suarez, Mexico, Mexico.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiparkinson Agents / administration & dosage
Ceruloplasmin / cerebrospinal fluid*,  metabolism
Copper / metabolism
Enzyme Activation / physiology
Iron / metabolism
Levodopa / administration & dosage
Middle Aged
Oxidative Stress / physiology
Parkinson Disease / cerebrospinal fluid*,  drug therapy,  enzymology*
Reg. No./Substance:
0/Antiparkinson Agents; 0/Levodopa; 7439-89-6/Iron; 7440-50-8/Copper; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Stress-induced changes of norepinephrine uptake sites in the locus coeruleus of C57BL/6J and DBA/2J ...
Next Document:  Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral scleros...